Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Kodiak Sciences Inc (KOD)
Kodiak Sciences Inc (KOD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 322,178
  • Shares Outstanding, K 52,472
  • Annual Sales, $ 0 K
  • Annual Income, $ -333,820 K
  • 60-Month Beta 2.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.92
Trade KOD with:

Options Overview Details

View History
  • Implied Volatility 93.68% ( +11.16%)
  • Historical Volatility 122.39%
  • IV Percentile 47%
  • IV Rank 33.03%
  • IV High 267.63% on 11/06/23
  • IV Low 7.88% on 09/25/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 8
  • Volume Avg (30-Day) 166
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 2,345
  • Open Int (30-Day) 3,574

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.99
  • Number of Estimates 3
  • High Estimate -0.76
  • Low Estimate -1.27
  • Prior Year -1.35
  • Growth Rate Est. (year over year) +26.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.69 +58.51%
on 02/05/24
6.27 -6.70%
on 02/27/24
+0.87 (+17.47%)
since 01/26/24
3-Month
2.31 +153.25%
on 12/01/23
6.27 -6.70%
on 02/27/24
+3.19 (+119.92%)
since 11/28/23
52-Week
1.37 +327.01%
on 10/27/23
9.80 -40.31%
on 06/07/23
-0.65 (-10.00%)
since 02/28/23

Most Recent Stories

More News
Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

KOD : 5.85 (-4.72%)
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

KOD : 5.85 (-4.72%)
New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

Tarcocimab demonstrated strong durability, matched efficacy and comparable safety versus aflibercept in a head-to-head comparative pivotal trial over one-year...

KOD : 5.85 (-4.72%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. ("Kodiak" or the "Company") (NASDAQ: KOD). Such investors...

KOD : 5.85 (-4.72%)
Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

KOD : 5.85 (-4.72%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. ("Kodiak" or the "Company") (NASDAQ: KOD). Such investors...

KOD : 5.85 (-4.72%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. ("Kodiak" or the "Company") (NASDAQ: KOD). Such investors...

KOD : 5.85 (-4.72%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. ("Kodiak" or the "Company") (NASDAQ: KOD). Such investors...

KOD : 5.85 (-4.72%)
Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

/PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ: KOD) announced today topline results from three Phase 3 studies of tarcocimab tedromer, a novel antibody...

KOD : 5.85 (-4.72%)
Kodiak Sciences to Present at Upcoming Investor Conferences

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

KOD : 5.85 (-4.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Kodiak Sciences Inc. is a clinical stage biopharmaceutical company engaged in developing novel therapeutics to treat chronic, high-prevalence retinal diseases, which are the major causes of blindness. The company's proprietary antibody biopolymer conjugate (ABC) platform is designed to maintain potent...

See More

Key Turning Points

3rd Resistance Point 6.52
2nd Resistance Point 6.36
1st Resistance Point 6.11
Last Price 5.85
1st Support Level 5.69
2nd Support Level 5.53
3rd Support Level 5.28

See More

52-Week High 9.80
Fibonacci 61.8% 6.58
Last Price 5.85
Fibonacci 50% 5.59
Fibonacci 38.2% 4.59
52-Week Low 1.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar